Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review3-MATIDA
Discontinued Product
2196 has been discontinued.
View all Glutamate (Metabotropic) Group I Receptors products.
Description: Potent and selective mGlu1 antagonist
Chemical Name: α-Amino-5-carboxy-3-methyl-2-thiopheneacetic acid
Purity: ≥99% (HPLC)
Biological Activity for 3-MATIDA
Potent metabotropic glutamate mGlu1 receptor antagonist (IC50 = 6.3 μM at rat mGlu1a). Displays ≥ 40-fold selectivity over other receptors: mGlu5, mGlu2, mGlu4a (IC50 > 300 μM), NMDA and AMPA (IC50 = 250 μM). Neuroprotective in cultured murine cortical cells and rat hippocampal slice cultures in vitro. Reduces the volume of ischemia-induced brain infarcts in rats following systemic administration in vivo.
Technical Data for 3-MATIDA
| M. Wt | 215.23 |
| Formula | C8H9NO4S |
| Storage | Store at +4°C |
| Purity | ≥99% (HPLC) |
| CAS Number | 518357-51-2 |
| PubChem ID | 10398360 |
| InChI Key | KOMWRBFEDDEWEP-UHFFFAOYSA-N |
| Smiles | CC1=C(SC(=C1)C(O)=O)C(N)C(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for 3-MATIDA
References for 3-MATIDA
References are publications that support the biological activity of the product.
Moroni et al (2002) The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death. Neuropharmacology 42 741 PMID: 12015200
Cozzi et al (2002) Metabotropic glutamate 1 (mGlu1) receptor antagonists enhance GABAergic neurotransmission: a mechanism for the attenuation of post-ischemic injury and epileptiform activity? Neuropharmacology 43 119 PMID: 12213266
Constantino et al (2004) Stereoselective synthesis and preliminary evaluation of (+)- and (-)-3-methyl-5-carboxy-thien-2-yl-glycine (3-MATIDA): identification of (+)-3-MATIDA as a novel mGluR1 competitive antagonist. Il Farmaco 59 93 PMID: 14871500
View Related Products by Target
View Related Products by Product Action
View all Glutamate (Metabotropic) Group I Receptor Antagonists
Keywords: 3-MATIDA, 3-MATIDA supplier, Potent, selective, mGlu1, mGluR1, antagonists, mGlur, Group, I, Receptors, mGlu5, mGluR5, Glutamate, Metabotropic, (Metabotropic), 2196, Tocris Bioscience
1 Citation for 3-MATIDA
Citations are publications that use Tocris products. Selected citations for 3-MATIDA include:
Zheng and Raman (2011) Prolonged postinhibitory rebound firing in the cerebellar nuclei mediated by group I metabotropic glutamate receptor potentiation of L-type calcium currents. J Neurosci 31 10283 PMID: 21753005
Reviews for 3-MATIDA
There are currently no reviews for this product. Be the first to review 3-MATIDA and earn rewards!
Have you used 3-MATIDA?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.